Navigation Links
Duska Therapeutics to Present at Noble Financial Equity 'M.A.D. MAX' Conference on Tuesday, August 19th at 1:30 p.m. PDT
Date:8/19/2008

LA JOLLA, Calif., Aug. 19 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska") announced today that its CEO, James S. Kuo, M.D., M.B.A. will present at the fourth annual Noble Financial Equity Conference on Tuesday, August 19, 2008 at the Loews Lake Las Vegas Resort in Las Vegas, Nevada. Duska's presentation is scheduled for 1:30 p.m. PDT. Dr. Kuo will also be available for one-on-one meetings throughout the day.

The presentation with streaming video and PowerPoint will be webcast live and archived on Noble Financial's conference website at http://www.noblemadmax.com. Participants should register at least 10 minutes prior to the start of the presentation to ensure timely access.

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Duska is developing a portfolio of investigational medicines, two of which are in late stages of clinical testing. Duska's ATPace(TM) is expected to enter a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Duska has a preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For more information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, including the statements that Duska will present at the fourth annual Noble Financial Equity Conference on Tuesday, August 19, 2008 at the Loews Lake Las Vegas Resort in Las Vegas, Nevada. Duska's presentation is scheduled for 1:30 p.m. PDT. Dr. Kuo will also be available for one-on-one meetings throughout the day. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
2. Duska Therapeutics Obtains Standard & Poors Listing
3. Arno Therapeutics Announces Second Quarter 2008 Financial Results
4. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
5. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
6. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
9. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
10. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... For the months of ... a Spotlight series on “Cell Therapy Regulation” for its regenerative medicine ... on the unique regulatory challenges of stem cell medical research. , Stem cell ...
(Date:6/20/2017)... Rocky Hill, CT (PRWEB) , ... June 20, ... ... entrepreneurial support, today announced that the CTNext board of directors has formed a ... developed by a working group composed of institution presidents and other high-ranking representatives ...
(Date:6/20/2017)... ... ... Do More with OHAUS , With the launch of the new laboratory ... industry, to extending its expertise across the entire laboratory to a range of life ... allowing for its customers to 'Do More' in the lab. , Efficiency and ...
(Date:6/19/2017)... ... June 19, 2017 , ... A colony of healthy honey bees ... tissues by delivering pollen and nectar containing nutrients necessary for growth and survival. Better ... , Many recent indicators point to a decline in honey bee health. Sick and ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):